Actively Recruiting
Fisetin Intervention Study in Mild Alzheimer's Disease
Led by Sunnybrook Health Sciences Centre · Updated on 2026-04-13
5
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
S
Sunnybrook Health Sciences Centre
Lead Sponsor
S
Sunnybrook Research Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and tolerability of a natural health product called fisetin in older adults diagnosed with mild cognitive impairment or mild Alzheimer's disease dementia. This pilot study aims to better understand how fisetin may affect individuals with these neurocognitive conditions. The study is sponsored by Sunnybrook Health Sciences Centre and is conducted as a Phase 2 clinical trial. Participants will receive fisetin at a dose of 20 mg per kilogram of body weight daily. The study focuses on monitoring adverse events related to the treatment over a period of 30 days. There is no placebo or comparison group mentioned, and the study is not blinded. The intervention is designed to assess safety rather than effectiveness at this stage. During the study, participants will be observed for any treatment-emergent adverse events to determine fisetin's safety and tolerability. Assessments include cognitive tests such as the MoCA score, and researchers will monitor participants' overall health to ensure it is safe to continue. The total participation time for outcome measurement is 30 days, with follow-up to track any emerging issues during this period.
CONDITIONS
Brief Title
Fisetin in Mild Alzheimer's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Mild cognitive impairment due to Alzheimer's disease OR mild Alzheimer Dementia
- MoCA score of 11 or higher
- Stable psychotropics and cognitive enhancing medications
You will not qualify if you...
- Known hypersensitivity or allergy to fisetin
- Any medical condition or abnormal blood test that puts the subject at risk or prevents trial completion
- Unstable medical disorders
- Ongoing treatment for active infection with antibiotics/antifungals
- Ongoing treatment for cancer
- Active alcohol or substance use disorder
- Recent active bleeding
- Taking oral anticoagulants, anti-cancer, anti-seizure medications, or other drugs interacting with fisetin
- Use within last month of senolytic supplements, antioxidant supplements, or natural health products
- Other neurologic or neurodegenerative conditions affecting cognition
- Active major depressive episode, active suicidal thoughts, or psychosis
- Any condition preventing MRI scan participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 30 days
Participants receive fisetin 20mg/kg/day as part of the study treatment.
Visits as needed for safety monitoring during treatment
Trial Site Locations
Total: 1 location
1
Sunnybrook Research Institute
Toronto, Ontario, Canada, M4N 3M5
Actively Recruiting
Research Team
S
Study Coordinator
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here